Analisis Dimensi Kualitas Pelayanan Pasien Rawat Inap Bpjs Di Ruang Tulip Rumah Sakit Umum Daerah (RSUD) Djojonegoro Kabupaten Temanggung

Public service is considered satisfying and brings satisfactory when the service comes to fulfill the society's needs and demands. When the society doesn't feel satisfy by the given service, it can be concluded that the given service doesn't meet its quality and efficiency. To assess whether a public service provided in a good quality or not, the researcher uses the five dimensions measuring the quality of service by Zeithaml, et.al. The present research aims at describing and analyzing the BPJS public service opname patient at Tulip Room at Tulip Room in RSUD Temanggung Regency. The analysis can be seen from the dimensions of physical evidence, reliability, responsiveness, assurance, and empathy. The study deploys qualitative descriptive method by recruiting 7 informants. The informants are the BPJS opname patients. The result of the study showed that the quality of healthy public service at Tulip Room at Tulip Room in RSUD Temanggung Regency is optimal. It can be seen from the scheduled appropriate time of service, the responsive response to the patients by the staff, a good security service, and respecting the patients' priority. From the research, it can be recommended that to increase the hospitality at Tulip Room in RSUD Temanggung Regency, the hospital is in need of a set of security cover to enhance the patients' convenience by the noisy from inside and outside the Tulip Room that are in under renovation. In addition, to increase public participation, an information board is needed where the society can give complaints and suggestions to a better quality of the hospital and keep updating the information on the information board

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Background: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety. Methods: PROTECT is an international, randomised, double-blind, active-controlled study, being conducted in 134 clinical practice sites in 18 countries. The study examines sparsentan versus irbesartan in adults (aged ≥18 years) with biopsy-proven IgA nephropathy and proteinuria of 1·0 g/day or higher despite maximised renin-angiotensin system inhibitor treatment for at least 12 weeks. Participants were randomly assigned in a 1:1 ratio to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by estimated glomerular filtration rate at screening (30 to 1·75 g/day). The primary efficacy endpoint was change from baseline to week 36 in urine protein-creatinine ratio based on a 24-h urine sample, assessed using mixed model repeated measures. Treatment-emergent adverse events (TEAEs) were safety endpoints. All endpoints were examined in all participants who received at least one dose of randomised treatment. The study is ongoing and is registered with ClinicalTrials.gov, NCT03762850. Findings: Between Dec 20, 2018, and May 26, 2021, 404 participants were randomly assigned to sparsentan (n=202) or irbesartan (n=202) and received treatment. At week 36, the geometric least squares mean percent change from baseline in urine protein-creatinine ratio was statistically significantly greater in the sparsentan group (-49·8%) than the irbesartan group (-15·1%), resulting in a between-group relative reduction of 41% (least squares mean ratio=0·59; 95% CI 0·51-0·69; p<0·0001). TEAEs with sparsentan were similar to irbesartan. There were no cases of severe oedema, heart failure, hepatotoxicity, or oedema-related discontinuations. Bodyweight changes from baseline were not different between the sparsentan and irbesartan groups. Interpretation: Once-daily treatment with sparsentan produced meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy. Safety of sparsentan was similar to irbesartan. Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan. Funding: Travere Therapeutics